Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non-small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)

被引：0
|
作者：
Smit, E. F. [1 ]
Felip, E. [2 ]
Uprety, D. [3 ]
Nagasaka, M. [4 ]
Nakagawa, K. [5 ]
Paz-Ares, L. [6 ]
Pacheco, J. [7 ]
Li, B. T. [8 ]
Planchard, D. [9 ]
Baik, C. S. [10 ]
Goto, Y. [11 ]
Murakami, H. [12 ]
Pereira, K. M. C. [13 ]
Taguchi, A. [14 ]
Kogo, M. [14 ]
Kuwahara, Y. [13 ]
Zou, M. [13 ]
Feng, W. [13 ]
Tsuchihashi, Z. [13 ]
Janne, P. A. [15 ]
机构：
[1] Univ Med Ctr, Dept Pulm Dis, Leiden, Netherlands
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Barbara Ann Karmanos Canc Inst, Med Oncol, Detroit, MI USA
[4] Univ Calif Irvine, Sch Med, Med, Orange, CA USA
[5] Kindai Univ Hosp, Med Oncol, Osaka, Japan
[6] Clin Univ Navarra, Med Oncol, Madrid, Spain
[7] Univ Colorado, Ctr Canc, Internal Med, Med Oncol, Aurora, IL USA
[8] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[9] Gustave Roussy, Med Oncol, Villejuif, France
[10] Univ Washington, Med Oncol, Seattle, WA USA
[11] Natl Canc Ctr, Thorac Oncol Dept, Tokyo, Japan
[12] Shizuoka Canc Ctr, Med Oncol, Shizuoka, Japan
[13] Daiichi Sankyo Inc, Oncol, Basking Ridge, NJ USA
[14] Daiichi Sankyo Co Ltd, Oncol, Tokyo, Japan
[15] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2875
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151P
引用
收藏
页码：S241 / S242
页数：2
相关论文
共 50 条
  • [21] A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC)
    Kumar, Prashanth Ashok
    Sandhu, Michael
    Sravanthi, Metlapalli Venkata
    Kumar, Vishnu Charan Suresh
    Benjamin, Sam
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
    Smit, E. F.
    Felip, E.
    Uprety, D.
    Nakagawa, K.
    Paz-Ares, L.
    Pacheco, J.
    Li, B. T.
    Planchard, D.
    Baik, C.
    Goto, Y.
    Murakami, H.
    Saltos, A.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Yan, Q.
    Feng, W.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S994 - S995
  • [23] Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
    Nakagawa, K.
    Nagasaka, M.
    Felip, E.
    Pacheco, J.
    Baik, C.
    Goto, Y.
    Saltos, A.
    Li, B.
    Udagawa, H.
    Gadgeel, S.
    Murakami, H.
    Planchard, D.
    Bazhenova, L.
    Paz-Ares, L.
    Perol, M.
    Mazieres, J.
    Barlesi, F.
    Saxena, K.
    Shiga, R.
    Acharyya, S.
    Cheng, Y.
    Shahidi, J.
    Janne, P.
    Smit, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S109 - S110
  • [24] Circulating tumor DNA (ctDNA)-the next generation biomarker in non-small cell lung cancer patients treated with immunotherapy?
    Hydbring, Per
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (09) : 2103 - 2105
  • [25] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
    Borghaei, Hossein
    Besse, Benjamin
    Bardia, Aditya
    Mazieres, Julien
    Popat, Sanjay
    Augustine, Bincy
    D'amelio, Anthony Michael
    Barrios, Daniel
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Pleclinical investigation of T-DXd internalization and payload release in HER2 mutant non-small cell lung cancer cells
    Yamasaki, Atsushi
    Ikuta, Misa
    Abe, Manabu
    Deguchi, Tsuneo
    Kamai, Yasuki
    Nakamaru, Kenji
    Agatsuma, Toshinori
    CANCER RESEARCH, 2022, 82 (12)
  • [27] Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer
    Gregorc, V
    Ceresoli, GL
    Floriani, I
    Spreafico, A
    Bencardino, KB
    Ludovini, V
    Pistola, L
    Mihaylova, Z
    Tofanetti, FR
    Ferraldeschi, M
    Torri, V
    Cappuzzo, F
    Crinò, L
    Tonato, M
    Villa, E
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6006 - 6012
  • [28] Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
    Planchard, D.
    Brahmer, J. R.
    Yang, J. C-H.
    Kim, H. R.
    Li, R. K.
    Han, J-Y.
    Cortinovis, D. L.
    Runglodvatana, Y.
    Nakajima, E.
    Ragone, A.
    Winter, M.
    Gustavson, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [29] Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer
    Tarantino, Paolo
    Lee, Do
    Foldi, Julia
    Soulos, Pamela R.
    Gross, Cary Philip
    Grinda, Thomas
    Winer, Eric P.
    Lin, Nancy U.
    Krop, Ian E.
    Tolaney, Sara M.
    Lustberg, Maryam B.
    Sammons, Sarah L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan
    Yun, Karen M.
    Bazhenova, Lyudmila
    BMJ CASE REPORTS, 2023, 16 (05)
12345